Cargando…
Trajectory of clinical symptoms in relation to amyloid chronicity
INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clini...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489232/ https://www.ncbi.nlm.nih.gov/pubmed/36187195 http://dx.doi.org/10.1002/dad2.12360 |
_version_ | 1784792832825884672 |
---|---|
author | Birdsill, Alex C. Koscik, Rebecca L. Cody, Karly A. Jonaitis, Erin M. Cadman, Robert V. Erickson, Claire M. Chin, Nathaniel A. Przybelski, Robert J. Carlsson, Cynthia M. Asthana, Sanjay Christian, Bradley T. Eisenmenger, Laura B. Betthauser, Tobey J. Johnson, Sterling C. |
author_facet | Birdsill, Alex C. Koscik, Rebecca L. Cody, Karly A. Jonaitis, Erin M. Cadman, Robert V. Erickson, Claire M. Chin, Nathaniel A. Przybelski, Robert J. Carlsson, Cynthia M. Asthana, Sanjay Christian, Bradley T. Eisenmenger, Laura B. Betthauser, Tobey J. Johnson, Sterling C. |
author_sort | Birdsill, Alex C. |
collection | PubMed |
description | INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clinical Dementia Rating–Sum of Boxes (CDR‐SB) relative to estimated years of amyloid positivity (A+) in n = 123 participants who were all A+ based on [C‐11]Pittsburgh compound B positron emission tomography. RESULTS: The average amyloid chronicity at CDR‐SB of 2.5 was 20.1 years. The average trajectory of CDR‐SB accelerated after 10 years of elevated amyloid and varied greatly between 10 and 30 years. Exploratory analyses suggested that older age and higher volume of white matter hyperintensities shortened the interval between amyloid onset and cognitive impairment. DISCUSSION: The recontextualization of amyloid burden into the time domain will facilitate studies of disease progression, the influence of co‐pathology, and factors that hasten or slow cognitive impairment. |
format | Online Article Text |
id | pubmed-9489232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94892322022-09-30 Trajectory of clinical symptoms in relation to amyloid chronicity Birdsill, Alex C. Koscik, Rebecca L. Cody, Karly A. Jonaitis, Erin M. Cadman, Robert V. Erickson, Claire M. Chin, Nathaniel A. Przybelski, Robert J. Carlsson, Cynthia M. Asthana, Sanjay Christian, Bradley T. Eisenmenger, Laura B. Betthauser, Tobey J. Johnson, Sterling C. Alzheimers Dement (Amst) Disease Heterogeneity INTRODUCTION: While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum. METHODS: We examined trajectories of Clinical Dementia Rating–Sum of Boxes (CDR‐SB) relative to estimated years of amyloid positivity (A+) in n = 123 participants who were all A+ based on [C‐11]Pittsburgh compound B positron emission tomography. RESULTS: The average amyloid chronicity at CDR‐SB of 2.5 was 20.1 years. The average trajectory of CDR‐SB accelerated after 10 years of elevated amyloid and varied greatly between 10 and 30 years. Exploratory analyses suggested that older age and higher volume of white matter hyperintensities shortened the interval between amyloid onset and cognitive impairment. DISCUSSION: The recontextualization of amyloid burden into the time domain will facilitate studies of disease progression, the influence of co‐pathology, and factors that hasten or slow cognitive impairment. John Wiley and Sons Inc. 2022-09-20 /pmc/articles/PMC9489232/ /pubmed/36187195 http://dx.doi.org/10.1002/dad2.12360 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Disease Heterogeneity Birdsill, Alex C. Koscik, Rebecca L. Cody, Karly A. Jonaitis, Erin M. Cadman, Robert V. Erickson, Claire M. Chin, Nathaniel A. Przybelski, Robert J. Carlsson, Cynthia M. Asthana, Sanjay Christian, Bradley T. Eisenmenger, Laura B. Betthauser, Tobey J. Johnson, Sterling C. Trajectory of clinical symptoms in relation to amyloid chronicity |
title | Trajectory of clinical symptoms in relation to amyloid chronicity |
title_full | Trajectory of clinical symptoms in relation to amyloid chronicity |
title_fullStr | Trajectory of clinical symptoms in relation to amyloid chronicity |
title_full_unstemmed | Trajectory of clinical symptoms in relation to amyloid chronicity |
title_short | Trajectory of clinical symptoms in relation to amyloid chronicity |
title_sort | trajectory of clinical symptoms in relation to amyloid chronicity |
topic | Disease Heterogeneity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489232/ https://www.ncbi.nlm.nih.gov/pubmed/36187195 http://dx.doi.org/10.1002/dad2.12360 |
work_keys_str_mv | AT birdsillalexc trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT koscikrebeccal trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT codykarlya trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT jonaitiserinm trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT cadmanrobertv trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT ericksonclairem trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT chinnathaniela trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT przybelskirobertj trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT carlssoncynthiam trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT asthanasanjay trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT christianbradleyt trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT eisenmengerlaurab trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT betthausertobeyj trajectoryofclinicalsymptomsinrelationtoamyloidchronicity AT johnsonsterlingc trajectoryofclinicalsymptomsinrelationtoamyloidchronicity |